OUR MISSION
We want to consolidate our leadership and continue our growth path.
We are committed to implementing a continuous growth process through:
For over twenty years, we have been the Italian leader in diabetes development and supply of outpatient medical record software, and we have expanded the scope of our solutions to other specialized areas of chronic disease. We aim to further expand the reach of our electronic medical record software in the outpatient management of chronic diseases and become a national benchmark.
We strongly believe in the value of interoperability clinical software and are committed to developing integrations between our solution and our clients' IT infrastructure on a daily basis. We offer telemedicine systems natively integrated with the medical record and fully responsive to televisits, telemonitoring, and teleconsultation needs.
We want to export Meteda's culture and experience outside the Italian panorama, and we do so by building on the international vocation inherent in our DNA. Our current strategy is to find synergies with those who, like us, want to embrace the challenge of innovation in diabetes and nutrition.
For this reason, we are actively engaged in developing partnerships supported by EU funds for research and development projects for innovative solutions in the fields of diabetes and nutrition.
We have been operating in the Italian nutrition market for fifteen years, both in private practice and in hospitals. We are leaders in the development of software for personalized diets and are experiencing strong growth in the field of body composition measurement in outpatient settings. We intend to strengthen the Metadieta Academy project to offer our clients the best opportunities for professional development.
Pioneers in the development of the first remotely usable bioimpedance meter, We are committed to its daily application in a telemedicine nutritional counseling setting
In 2021, we entered the artificial intelligence market through the acquisition of the Portuguese company Retmarker S.A., the creator and manufacturer of an algorithm for screening diabetic retinopathy.
We also own algorithms developed in-house for predicting the onset of the main complications of diabetes. and we are committed to their clinical deployment in both the Italian and international markets. Furthermore, we are continuing our multi-year plan of intense investment in research and development for new AI applications in the clinical field.